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Department of Dermatology, University of Miami S chool of Medicine, (JLMcC. GDWJ, Miami, Florida. and 
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Dihydrofolate reductase (DHFR) inhibitors, which differ from the classical folate antago-
nists in physicochemical and pharmacologic parameters such as lipid solubility and mecha-
nisms of cellular transport, were screened for DHFR inhibitory activity and biologic activity 
in newborn rat skin. The most effective drugs from this screen were tested for their effects on 
de novo DNA synthesis in psoriatic epidermis in vitro. Of the 24 compounds studied, 
methotrexate (MTX) was the most potent inhibitor of rat skin DHFR (1,,11 = 8.6 x 10-u M ). 
Methotrexate-dimethylester, methasquin-diethylester, DDEP (2,4-diamino-5-(3' ,4' -dichlo-
rophenyl)-6-ethylpyrimidine), and Baker's triazine antifolate (NSC 139105), while less effec-
tive than MTX as DHFR inhibitors, were more effective than MTX as inhibitors of de novo 
DNA synthesis in rat skin in vitro. Baker's antifolate was the only compound tested which 
was considerably more effective than MTX as an inhibitor of de novo DNA synthesis in 
psoriatic epidermis in vitro. 
The folic acid antagonists, aminopterin and 
methotrexate (MTX), have played an important 
role in the systemic therapy of extensive psoriasis 
Ll-3]. Despite the theoretical and experimental 
evidence to support the concept of topical therapy, 
MTX has been ineffective when applied directly to 
psoriatic patches [4-8]. One of the reasons for the 
lack of topical activity ofMTX appears to be inade-
quate percutaneous penetration I9J. In a previous 
report we have shown that increasing the lipo-
philic character of the MTX molecule, either by 
chlorination or esterification, enhances percuta-
neous penetration 191. To obtain a better under-
standing of the action of these folic acid antago-
nists in skin, we have selected a series oflipophilic 
folic acid analogues representing different struc-
tural types, to study their enzyme inhibitory activ-
ity and biologic action in skin. 
MATERIALS AND METHODS 
MTX was obtained from Lederle Laboratories, Pearl 
River, N.Y., through the courtesy of Dr. E. C. De 
Manuscript received October 22, 1976; accepted for 
publication January 27, 1977. 
This investigation was supported in part by USPHS 
Grant 14887 from the Nationallnstitutes of Health, the 
Comprehensive Cancer Center of Miami Grant CA 
14395, and by the Dermatology Foundation ofMaimi. 
Reprint requests to: Dr. J. L. McCullough, Depart-
ment of Dermatology, University of Miami School of 
Medicine, P .O. Box 520875, Biscayne Annex, Miami, 
Florida 35152. 
Abbreviations: 
DDEP: 2,4-diamino-5-(3' ,4' -dichloropheny0-6-eth-
ylpyrimidine 
DHFR: dihydrofolate reductase 
MIR: mean inhibitory ratio 
MTX: methotrexate 
Renzo. MTX- dimethylester was provided by Dr. D. G. 
Johns. National Cancer Institute. National Institutes 
of Health, Bethesda, Md. The series of substituted 
quinazolines were synthesized. The ser ies of substi-
tuted 4,6-diaminotriazines were provided by Dr. B. R. 
Baker, Department of Chemistry, University of Cali-
fornia, Santa Barbara, Calif. Pyrimethamine and 
DDEP (2,4-diamino-5-(3' ,4 '-dichlorophenyl !-6-ethyl-
pyrimidinel were provided by Dr. C. A. Nichol, Bur-
roughs Wellcome & Company, Raleigh, N.C. Trimeth-
oprim was purchased from Calbiochem. The folate 
antagonists were dissolved in dimethylsuJf-
oxide:ethanol:emulphor EL-620 (GAP Corpl:water 
(1:1:5:93). 
Dihydrofolate was prepared from folate by t he dithio-
nite method of Futterman 110] as modified by Blakley 
i ll], and was stored frozen in suspension in 0.001 N HCI 
under nitrogen. NADPH was purchased from Sigma 
Chemical Company. 
Dihydrofolate reductase (DHFRl was partially puri-
fied from newborn rat skin <3-5 days old> utilizing the 
technique previously described 112 1. The 45-85~ ammo-
nium sulfate enzyme fraction was employed for these 
studies. 
A ssay for Inhibition of DihydrojiJ/ate Rl'ductase 
DHFR activity was measured by a spectrophotomet-
ric method utilizing the decrease in absorbance that 
occurs at 340 miL when NADPH and dihydrofolate are 
converted to NADP and tetrahydrofolate, respectively 
113]. Assays were performed at 37•c using a Gilford 
Model 2400 spectrophotometer and a n expanded scale of 
0-0.25 A. For the assay of enzyme activity in the inhibi-
tor studies, the reaction mixture contained in a total 
volume of 1 ml: Tris- HCI buffer, pH 7.5, 100 ILmoles; 
KCI, 150 j.Lmoles; NADPH, 0.05 J.Lmole; dihydrofolate, 
0.03 J.Lmole; and 2-mercaptoethanol, I J.Lmole. The mix-
ture was mixed and allowed to incubate at 37•c for 2 
min before sufficient DHFR was added to give an unin-
hibited rate of 0.8 absorbance units/10 min. Several 
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inhibitor concentrations were studied for each com-
pound in order to determine the concentration neces-
sary to obtain 50% inhibition (1, 11). 
A ssay fur Inhibttion of de nouo DNA Synthesis 
The inhibition of DNA synthesis was assayed by 
measuring the drug effect on the incorporation of 
I~H)deoxyuridine into the DNA of skin biopsy speci-
mens in vitro. Skin punch biopsies were obtained from 
psoriatic plaques or newborn rats of age 3 to 5 days. l'wo 
4-mm biopsy sections were weighed and incubated for 2 
hr in Eagle's medium containing I0- 1; M drug and 
I:'H]deoxyuridine, as previously described 114]. A mini-
mum of three samples were tested for each control and 
drug. The tissues were washed thoroughly with cold 
0.25 N PCA and homogenized in 2 ml of water. l'wo 
hundred microliters of homogenate were collected on a 
Millipore filter (HA WP 1300) using a 3025 Millipore 
Manifold, and washed sequentially with saline, 5'*" 
TCA (2x), 70% ethanol . and 100'*" ethanol 1151. The 
filters were dried and counted in Liquifluor (New Eng-
land Nuclear) in a scintillation spectrometer. Counts 
were corrected for background and expressed as counts/ 
min/mg of t issue. A mean inhibitory ratio <MIRl was 
cah:ulated for each drug (± S.D.l to express its activ1ty 
relative to IQ-" M MTX : 
MIR = ! Inhibition by 10 .; M test drug 
'*" Inhibition by 10 1; M MTX 
Since the object of the study was to compare the 
relative effectiveness of the various folate antagonists 
with MTX, a concentration of MTX of 10 " M . was 
chosen which inhibited DNA synthesis approximately 
50% 114]. 
RESULTS 
lnhibitor:v Al"fiuit_v of" Folic Acid Antagonists in 
Rat Skin 
MTX, the classical folic acid antagonist, is a 
potent inhibitor of newborn rat sk in DHFR with 
an I:,, of8.6 x 10 " M . The DHFR inhibitory activi-
ties tl:,, values) a nd DNA inhibitory activities 
(MIR values) obtained for the diOerent structural 
classes of folic acid antagonists in newborn rat 
skin are shown in Tables 1- JV. 
The small molecule, 2.4-diaminopyrimidine in-
hibitors of DHFR, pyrimethamine and trimetho-
prim, have played an important role in the selec-
tive chemotherapy of microorganisms. These 
drugs are potent inhibitors of the microbial DHFR 
with negligible effects on the mammalian host 
DHFR [16]. Of all drugs tested in this study, pyri-
methamine and trimethoprim were the least ac-
tive inhibitors of rat skin DHFR. These drugs 
were aJso poor inhibitors of DNA synthesis in ral 
skin. The lipid-soluble dichJorophenyl pyrimidine, 
DDEP. has previously been shown to be consider-
ably more potent than pyrimethamine as an inhib-
itor of human erythrocyte DHFR, with an 1:,., of 
10 " M 1171. Of the 2,4-diaminopyrimidines tested, 
DDEP was the most active DHFR inhibitor (1:,, = 
1.9 x 15 x M ). DDEP was also more effective than 
MTX as an inhibitor of DNA synthesis (MIR = 
1.43). 
The quinazolines represent an important group 
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TABLE l. Inhibition by substituted 2 .4-diaminopyri.mi-
dines 
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TABLE IV. Inhibition by 4-6-diam inotriazines 
.. . tflllll,ltOtJ 
)oo!MJ lhtle C ~I .DJ 
·-
R 
" • ' 111.111 
-@:~.cooo~<v a.e . ao""' . .. o! .l. 
IIMZS 
0·~0· 4 I • 10""1 o.zo: .. 
lo.,t' 
12··· 
~"'0 • 0 • • ..-e 0 .• , :t ., 
. T?IS 
0·~· "· l .l. fO • • .. •• : , 4 8 
1110?'1: 




(:QICCH.Jr I D • 10""
1 I 1 0 ! 4 e 
111106 
of DHFR inhibitors which have been studied ex-
tensively as potential antineoplastic [18) and anti-
protozoal [19] agents. While most of the 2,4-dia-
minoquinazolines were potent inhibitors of DHFR 
(Tabs. 11, Ill), there were considerable differences 
in their DNA inhibitory activity. Of this group of 
compounds the most effective inhibitors of DNA 
synthesis were the diethylesters of chlorasquin 
and methasquin and compound H-332. The re-
maining quinazolines were less effective than 
MTX (MIR < ll. 
Certain substituted 4,6-diaminotriazines, syn-
thesized by Baker and Lourens [20] have been 
shown to be potent inhibitors of mammalian 
DHFR. These inhibitors can be divided into two 
groups: (1 l tight binding "reversible" inhibitors, 
and (2) "irreversible" inhibitors that contain a ter-
minal sulfonyl fluoride group which forms a cova-
lent bond with a nucleophilic group on the en-
zyme. The reversible and irreversible triazine in-
hibitors were all potent inhibitors of rat skin 
DHFR (Tab. IV). The most effective inhibitors of 
DNA synthesis were the reversible inhibitors 
133072 and 139105 and the irreversible inhibitor 
113423. 
Inhibitory A ctivity of Folic A cid A ntagonists in 
Psoriatic: Skin 
Selected compounds from each structural class 
showing effective DNA inhibitory activity in rat 
skin were studied for their activity in psoriatic 
epidermis in vitro (Tab. VJ. Inhibitory activity 
comparable to MTX was found with MTX di-
methylester and methasquin diethylester. Com-
pounds H332, 113423, and DDEP were less eflec-
tive than MTX. The inhibitory activities of MTX-
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TABLE V. Effect of folic acid antagonists on DNA 
synthesis in psoriatic skin 
Drug Mean inhibitory ratio 
MTX 







1.17 ::!:: .10 
0.97 ::!:: .19 
0.69 ± .35 
0.34 ± .17 
1.71 ::!:: .20 
0.83 ::!:: .31 
djmethylester and methasquin-diethylester were 
similar to that of MTX. The triazine inhibitor 
139105 was the only compound that was consider-
ably more effective than MTX as an inhibitor of 
DNA synthesis in psoriatic epidermis. 
DISCUSSION 
The folic acid antagonists have played an impor-
tant role in the chemotherapy of cancer, psoriasis, 
and bacterial and protozoal infections. Despite the 
diversified therapeutic actions of the folic acid an-
tagonists they are thought to share a common 
mode of action. The folic acid antagonists are po-
tent inhibitors of the target enzyme DHFR and 
thus interfere with the synthesis of reduced folate 
coenzymes. These folate coenzymes are required 
for metabolic reactions essential for cellular repl i-
cation 121]. 
In this investigation we have measured the in-
hibitory activity of various structural types of folic 
acid antagonists against isolated DHFR to assess 
potential drug inhibi tory activity in skin, in the 
absence of such pharmacologic considerations as 
transport to and into t he target basal cell. Most of 
the compounds tested were potent inhibitors of rat 
skin DHFR with 1;,11 values of J0- 7 to 10- • M . How-
ever, with the exception of chlorasquin, these 
drugs were less effective than MTX as inhibitors of 
DHFR. 
Although a knowledge of the inhibitory effect of 
a drug on DHFR activity may be of some value as 
a preliminary screen, it is not a sufficient criter ion 
to select potential drugs for clinical use. The dem-
onstration of biologic activity in an intact cellular 
system is of greater value for defining potentia l 
cytotoxic action . In this study, drug effect on de 
novo DNA synthesis was used to predict cytotoxic-
ity. There were several compounds representing 
the different structural classes of folic acid antago-
nists, which were more effective than MTX as 
inhibitors of DNA synthesis in rat skin, although 
they were less effective than MTX as inhibitors of 
DHFR. Thus, the difference in biologic activity 
must be related to other properties, such as lipo-
philicity of the drug affecting membrane trans-
port, and/or possible interaction with other re-
duced folate-requiring enzymes. 
Although several compounds were found to be 
more effective than MTX as inhibitors of DNA 
syn t hesis in rat skin, only the triazine an tifolate 
139105 was considerably more effective than MTX 
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in psoriatic epidermis. The reasons for the differ-
ences in inhibitory activity in these two tissues are 
not known. A contributing factor to the low activ-
ity of the triazine 113423 in psoriasis may be an 
enzymatic hydrolysis of the sulfonyl fluoride group 
as reported to occur in certain tissues 122]. 
In selecting a topically effective folic acid antag-
onist, the following factors must be considered: (lJ 
there must be effective percutaneous penetration 
of the drug to reach the basal cell layer; (2) the 
drug must tightly bind and inhibit the tartet en-
zyme DHFR in the epidermal basal cell; and (3) 
the consequence of this drug-enzyme interaction 
must lead to a biologic effect such as inhibition of 
DNA synthesis and/or mitosis, which decreases or 
inhibits epidermal cell proliferation. In this study 
we have selected from various structural types of 
folic acid antagonists those compounds which meet 
the basic requirements of (2J and (3J. Percuta-
neous penetration, an essential consideration in 
achieving a pharmacologic effect by the topical 
route of administration, is intimately related to 
the lipid solubility characteristics of the drug. 
MTX, which is a water-soluble drug, shows little 
penetration through intact human skin 19]. In-
creasing the lipophilic character of MTX by esteri-
fication and/or chlorination has been reported to 
enhance percutaneous penetration. Since the 
drugs selected for this study are more lipid soluble 
than MTX, they might fulfill the first requirement 
of effective percutaneous penetration and be of 
value for the topical treatment of psoriasis. 
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